GlassScriptPhysician profile
Muhammad N Khan
NPI 1861461451
$1,895.88
in general payments reported to CMS, 2019-2025
24 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $107 · 2021: $242 · 2022: $397 · 2023: $410 · 2024: $210 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $806.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $268.34 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $221.21 | 2022-2024 | Farxiga, Andexxa |
| Urovant Sciences INC | $217.41 | 2021-2022 | |
| Glaxosmithkline, LLC. | $137.26 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $136.87 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $122.93 | 2023-2025 | Zerbaxa, Dificid, Pifeltro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $116.61 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $115.00 | 2023 | Xarelto |
| Medtronic Vascular, INC. | $58.20 | 2020 | |
| Shionogi INC | $50.19 | 2024-2025 | Fetroja |
| Neurocrine Biosciences, INC. | $50.11 | 2023 | Ongentys, Ingrezza |
| Sumitomo Pharma America, INC. | $40.34 | 2023 | Gemtesa |
| Vertex Pharmaceuticals Incorporated | $33.79 | 2025 | |
| Abbvie INC. | $29.27 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $24.65 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Mylan Specialty L.P. | $24.00 | 2024 | Yupelri |
| Amgen INC. | $23.73 | 2025 | Repatha |
| 180 Medical, INC. | $22.14 | 2025 | |
| Lilly USA, LLC | $18.18 | 2023 | Amyvid |
| Pfizer INC. | $17.96 | 2022 | |
| Csl Behring | $17.58 | 2023 | Hizentra |
| Alnylam Pharmaceuticals INC. | $14.84 | 2022 | |
| Corium, LLC | $14.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.